Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed exchanges that its subsidiary, Optival Health Solutions Private Limited, received a suspension order from the Food and Drug Administration (FDA), Mumbai, for a drug license at its Vrindavan-Thane store in Maharashtra. The suspension is for five days under Rule 65 of the Drugs and Cosmetics Act, 1940, and the order was received on July 7, 2025. The potential revenue loss is estimated at approximately Rs 2.25 lakhs. The company has disclosed this under SEBI Listing Regulations as a routine compliance update.
The impact is negligible for shareholders — a single store license suspension for 5 days with a revenue loss of just Rs 2.25 lakhs is immaterial to Medplus's overall business. No meaningful effect on stock price or operations is expected.